Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Education & Training

  • Fellowship Program, Pediatric Neurosurgery, 2018
    UCSD/Rady Children's Hospital
  • Residency Program, Neurosurgery, 2017
    University of New Mexico Hospital
  • Fellowship Program, 2017
    University of New Mexico Hospital
  • Internship Program, Neurosurgery, 2012
    University of New Mexico Hospital
  • Fellowship Program, Neurosurgery, 2011
    University of New Mexico Hospital
  • MD, 2005
    St. George's University

National Provider ID: 1982922837


Biography

Carlos E. Sanchez, M.D., is currently an attending neurosurgeon at Children's National Health System and a principal investigator at the Center for Cancer and Immunology Research at the Children's Research Institute. He cares for all children with neurosurgical diseases, with a particular interest in the surgical treatment of brain tumors with endoscopic, robotic and skull base approaches, in addition to application of translational neuro-oncologic therapies in the operating room.

Dr. Sanchez completed a post-doctoral fellowship at the Massachusetts General Hospital focused in surgical oncology under the leadership of Bob S. Carter, M.D., Ph.D., followed by a residency in neurosurgery and fellowship in neuro-critical care at the University of New Mexico. He then completed a fellowship in pediatric neurosurgery at Rady Children's Hospital in San Diego, CA.

Dr. Sanchez's research interests include cellular engineering of CAR NK cells for brain tumor immunotherapy. He is an active member of the Congress of Neurological Surgeons and the AANS/CNS section on pediatric neurological surgery.

Sahin A, Sanchez C, Carter B, et al. Development of third generation anti-EGFRvIII chimeric t-cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. PLOS One. 2018. https://doi.org/10.1371/journal.pone.0199414.

Waters JD, Sanchez C, Sahin A, Carter B, et al. CT-322, a VEGF-R2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolamide and radiation therapy. J Neurooncology. 2012:110(1):37-48.

Sanchez CE, Gale J, Tierney TS, et al. Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum. Laboratory investigation. J Neurosurgery. 2011;114(3):672–680.

Bullain S, Sahin A, Szentirmai O, et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol. 2009;94(3):373-382.

Sanchez CE, Gale J, Thatcher J, Eskandar E, and Carter BS. (2009). Multiple-plane stereotactic brain targeting platform. (patent)

Bullain S, Sanchez CE, Mulligan RC, Carter BS. (2007). Cytotoxic t-lymphocytes genetically engineered to attack EGFRvIII mutation in human glioma. (patent)

Mitha A, Sanchez CE, Ogilvy CS. Surgical management of acute stroke patients. In: Greer, D. ed. Acute Ischemic Stroke: An Evidence Based Approach. New York: Wiley, 2007.